OA
NVO

Oxbow Advisors’s Novo Nordisk NVO Stock Holding History

Oxbow Advisors’s Portfolio NVO Stock Details NVO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-2,261
Closed -$269K – 227
2024
Q3 		$269K Hold
2,261
– – 0.03% 175
2024
Q2 		$323K Buy
2,261
+465
+26% +$61.6K 0.04% 177
2024
Q1 		$231K Buy
+1,796
New +$214K 0.03% 192
2018
Q3 		– Sell
-66,576
Closed -$1.53M – 306
2018
Q2 		$1.53M Buy
66,576
+1,984
+3% +$47.2K 0.2% 114
2018
Q1 		$1.59M Buy
64,592
+2,380
+4% +$62.5K 0.32% 87
2017
Q4 		$1.67M Sell
62,212
-800
-1% -$20.3K 0.31% 94
2017
Q3 		$1.52M Sell
63,012
-2,638
-4% -$59.6K 0.29% 97
2017
Q2 		$1.41M Buy
+65,650
New +$1.32M 0.25% 109

Other funds holding NVO

Jennison Associates
Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
GQG Partners
GQG Partners Ft. Lauderdale, Florida $63.1B AUM 23.07% 1-Year Est. Return
Fisher Asset Management
Fisher Asset Management Camas, Washington $295B AUM 31.6% 1-Year Est. Return
Koshinski Asset Management
Koshinski Asset Management Decatur, Illinois $1.6B AUM 20.7% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Loomis, Sayles & Company
Loomis, Sayles & Company Boston, Massachusetts $74.3B AUM 24.01% 1-Year Est. Return
Fayez Sarofim & Co
Fayez Sarofim & Co Houston, Texas $39.1B AUM 15.14% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
F
Folketrygdfondet Oslo Norway, Norway $5.64B AUM 47.16% 1-Year Est. Return

Oxbow Advisors's NVO Position: Q4 2024 in Review

Oxbow Advisors sold out of Novo Nordisk (NVO) in Q4 2024, closing a stake of 2,261 shares — an estimated $269K sold.

Oxbow Advisors first reported a position in NVO in Q2 2017 and held it in 8 quarters. The position peaked at $1.67M in Q4 2017. 1,663 funds tracked by Wall St. Rank hold NVO as of Q4 2024.

  • Oxbow Advisors reported no remaining Novo Nordisk position as of Q4 2024 after selling out during the quarter.
  • Oxbow Advisors sold 2,261 Novo Nordisk shares in Q4 2024, an estimated $269K.
  • Oxbow Advisors first reported a position in Novo Nordisk in Q2 2017 and held it in 8 quarters.
  • Oxbow Advisors's Novo Nordisk position peaked at $1.67M in Q4 2017.
  • 1,663 funds tracked by Wall St. Rank held Novo Nordisk as of Q4 2024.

Based on Oxbow Advisors's 13F filing for Q4 2024, filed 3 Feb 2025.